Oculis to Present Its Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis Holding AG announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC).

The presentation of the DME AWARE Delphi Study interim results will highlight key areas of consensus on unmet needs in DME patient management among leading global experts. Further insights from Stage 1 of the Phase 3 DIAMOND program reinforcing the efficacy and safety profile of OCS-01 eye drops for DME will also be shared. OCS-01 is being developed to be the first noninvasive treatment for DME, addressing key unmet needs for earlier treatment intervention and for inadequate responders to the current standard of care.

Data from the Phase 2b RELIEF trial investigating Licaminlimab (OCS-02) in signs of DED will be presented following positive and consistent results from phase 2 trials in symptoms. The genetic biomarker, previously identified, to predict response to Licaminlimab, enables the first genotype-based development plan to drive a personalized approach in dry eye disease (DED). Licaminlimab is being developed to transform the treatment paradigm in DED, currently driven by trial and error, and address unmet medical needs for this multifactorial disease with a dissatisfied patient population.

Details of the presentations are as follows:

Eyecelerator 2025

• Company showcases – Retina: TKI and Drug Delivery
  • Presenter: Sharon Klier, MD, Chief Development Officer
  • Date/Time: Friday, May 2, 2025, 1:30 PM – 3:00 PM MST

ARVO Annual Meeting 2025

• Interim results of the DME AWARE Delphi Study on unmet needs in DME patient management
  • Presenter: Anat Loewenstein, MD, MHA
  • Session: #261
  • Presentation: #2587
  • Posterboard: #B0300
  • Date/Time: Monday, May 5, 2025, 3:00 PM – 4:45 PM MST
• BCVA and CST Improvement over 12 weeks with OCS-01 Eye Drops in DME from DIAMOND Stage 1 trial
  • Presenter: Carl Danzig, MD
  • Session: 401
  • Presentation: #4011
  • Location: Room #255ABC
  • Date/Time: Wednesday, May 7, 2025, 10:15 AM – 12:00 PM MST
• Licaminlimab in the treatment of dry eye disease
  • Presenter: Anat Galor, MD, MSPH
  • Session: #513
  • Presentation: #5682
  • Posterboard: #B0077
  • Date/Time: Thursday, May 8, 2025, 8:00 AM – 9:45 AM MST

Retina World Congress 2025

• Wet AMD, DR, RVO – Part 2, Panel Discussion
  • Participant: Riad Sherif, MD, Chief Executive Officer
  • Date/Time: Thursday, May 8, 2025, 11:25 AM – 11:59 AM ET
• BCVA and CST Improvement over 12 weeks with OCS-01 Eye Drops in DME From DIAMOND-Stage 1 trial
  • Presenter: David Almeida, MD, PhD
  • Date/Time: Thursday, May 8, 2025, 6:08 PM – 6:13 PM ET